Rubric Capital Management (New York)’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Rubric Capital Management (New York)’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-719,809	Closed	-$16.7M	–	79
2023 Q1	$16.7M	Hold	719,809	–	–	0.43%	48
2022 Q4	$18.9M	Sell	719,809 -229,357	-24%	-$5.08M	0.82%	37
2022 Q3	$18.7M	Hold	949,166	–	–	0.94%	34
2022 Q2	$16.6M	Buy	949,166 +384,813	+68%	+$6.04M	0.87%	36
2022 Q1	$9.23M	Hold	564,353	–	–	0.33%	49
2021 Q4	$9.21M	Hold	564,353	–	–	0.44%	48
2021 Q3	$7.2M	Buy	564,353 +238,490	+73%	+$3.14M	0.2%	46
2021 Q2	$4.6M	Hold	325,863	–	–	0.29%	49
2021 Q1	$5.06M	Hold	325,863	–	–	0.3%	54
2020 Q4	$5.17M	Sell	325,863 -1	-0%	-$15	0.38%	52
2020 Q3	$3.96M	Hold	325,864	–	–	0.37%	53
2020 Q2	$3.76M	Buy	325,864 +151,644	+87%	+$2.09M	0.43%	47
2020 Q1	$2.39M	Buy	+174,220	New	+$2.06M	0.38%	47

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Rubric Capital Management (New York)'s KDNY Position: Q2 2023 in Review

Rubric Capital Management (New York) sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 719,809 shares — an estimated $16.7M sold.

Rubric Capital Management (New York) first reported a position in KDNY in Q1 2020 and held it in 13 quarters. The position peaked at $18.9M in Q4 2022. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

Rubric Capital Management (New York) reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Rubric Capital Management (New York) sold 719,809 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $16.7M.
Rubric Capital Management (New York) first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2020 and held it in 13 quarters.
Rubric Capital Management (New York)'s Chinook Therapeutics, Inc. Common Stock position peaked at $18.9M in Q4 2022.
185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2023, filed 11 Aug 2023.